Tumor Infiltrating Lymphocytes

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Tumor Infiltrating Lymphocytes is an early-stage landscape with 0 programs across 1 company. The most active players are Iovance Biotherapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Iovance Biotherapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Unknown status4 · 40%

Recruiting3 · 30%

Active, not recruiting2 · 20%

Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Recruiting·—·Phase 2·NCT03935893·240 enrolled

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT03645928·245 enrolled

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06598371·141 enrolled

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Active, not recruiting·AAgonOx, Inc.·Phase 1·NCT05902520·18 enrolled

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06237881·15 enrolled

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Terminated·—·Phase 1·NCT03991741·3 enrolled

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

Unknown status·—·Phase 2·NCT00610389·27 enrolled

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05342506·30 enrolled

A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors

Unknown status·SSun Yat-sen University·Phase 1·NCT01462903·20 enrolled

Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors

Unknown status·PPeking University·Phase 1·NCT05730361·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)